1. |
- Aguiar, Diana, et al.
(författare)
-
Transforming critical agrarian studies: : Solidarity, scholar-activism and emancipatory agendas in and from the Global South
- 2023
-
Ingår i: Journal of Peasant Studies. - 0306-6150. ; 50:2, s. 758-786
-
Tidskriftsartikel (refereegranskat)abstract
- This paper examines the challenges and opportunities faced bycritical agrarian scholars in and from the Global South. We arguethat despite the historical and structural limitations, the criticaljuncture of convergence of crises and renewed interest inagrarian political economies offers an opportunity for fostering adiverse research agenda that opens space for critical perspectivesabout, from and by the Global South, which is mostly absent inmainstream scholarship dominated by the Global North. We alsopropose doing so by enhancing solidarity to transform injusticeswithin academia and other spaces of knowledge production anddissemination. To develop the argument,first, we reflect on themultiplicity of crises in rural areas and the changing character ofsocial struggles, as well as the interlinkages betweenenvironmental crises and the re-emergence of critical agrarianstudies that are reshaping the agrarian question. Then, we discussthe implications and conditions of the political agenda carriedout by a scholar-activist movement working on agrarian studiesfrom the Global South. Drawing on our experience as theCollective of Agrarian Scholar-Activists from the South (CASAS),we conclude by proposing three ways forward for enhancingsolidarity through networks of scholar-activists: knowledgeaccessibility, cooperative organization, and co-production ofknowledge
|
|
2. |
- Axfors, Cathrine, et al.
(författare)
-
Association between convalescent plasma treatment and mortality in COVID-19 : a collaborative systematic review and meta-analysis of randomized clinical trials
- 2021
-
Ingår i: BMC Infectious Diseases. - : BioMed Central (BMC). - 1471-2334. ; 21:1
-
Forskningsöversikt (refereegranskat)abstract
- Background: Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, ). Methods: In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung-Knapp-Sidik-Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results: A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I-2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions: Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care.
|
|
3. |
- Rubio-Giménez, Víctor, et al.
(författare)
-
High-Quality Metal-Organic Framework Ultrathin Films for Electronically Active Interfaces.
- 2016
-
Ingår i: Journal of the American Chemical Society. - : American Chemical Society (ACS). - 1520-5126 .- 0002-7863. ; 138:8, s. 2576-2584
-
Tidskriftsartikel (refereegranskat)abstract
- Currently available methodologies arguably lack the exquisite control required for producing metal-organic framework (MOF) thin films of sufficient quality for electronic applications. By directing MOF transfer with self-assembled monolayers (SAMs), we achieve very smooth, homogeneous, highly oriented, ultrathin films across millimeter-scale areas that display moderate conductivity likely due to electron hopping. Here, the SAM is key for directing the transfer thereby enlarging the number and nature of the substrates of choice. We have exploited this versatility to evolve from deposition onto standard Si and Au to nonconventional substrates such as ferromagnetic Permalloy. We believe that this strategy might be useful for the integration of MOFs as active interfaces in electronic devices.
|
|